» Articles » PMID: 24947048

Single Cell Mutational Analysis of PIK3CA in Circulating Tumor Cells and Metastases in Breast Cancer Reveals Heterogeneity, Discordance, and Mutation Persistence in Cultured Disseminated Tumor Cells from Bone Marrow

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2014 Jun 21
PMID 24947048
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Therapeutic decisions in cancer are generally guided by molecular biomarkers or, for some newer therapeutics, primary tumor genotype. However, because biomarkers or genotypes may change as new metastases emerge, circulating tumor cells (CTCs) from blood are being investigated for a role in guiding real-time drug selection during disease progression, expecting that CTCs will comprehensively represent the full spectrum of genomic changes in metastases. However, information is limited regarding mutational heterogeneity among CTCs and metastases in breast cancer as discerned by single cell analysis. The presence of disseminated tumor cells (DTCs) in bone marrow also carry prognostic significance in breast cancer, but with variability between CTC and DTC detection. Here we analyze a series of single tumor cells, CTCs, and DTCs for PIK3CA mutations and report CTC and corresponding metastatic genotypes.

Methods: We used the MagSweeper, an immunomagnetic separation device, to capture live single tumor cells from breast cancer patients' primary and metastatic tissues, blood, and bone marrow. Single cells were screened for mutations in exons 9 and 20 of the PIK3CA gene. Captured DTCs grown in cell culture were also sequenced for PIK3CA mutations.

Results: Among 242 individual tumor cells isolated from 17 patients and tested for mutations, 48 mutated tumor cells were identified in three patients. Single cell analyses revealed mutational heterogeneity among CTCs and tumor cells in tissues. In a patient followed serially, there was mutational discordance between CTCs, DTCs, and metastases, and among CTCs isolated at different time points. DTCs from this patient propagated in vitro contained a PIK3CA mutation, which was maintained despite morphological changes during 21 days of cell culture.

Conclusions: Single cell analysis of CTCs can demonstrate genotypic heterogeneity, changes over time, and discordance from DTCs and distant metastases. We present a cautionary case showing that CTCs from any single blood draw do not always reflect metastatic genotype, and that CTC and DTC analyses may provide independent clinical information. Isolated DTCs remain viable and can be propagated in culture while maintaining their original mutational status, potentially serving as a future resource for investigating new drug therapies.

Citing Articles

Single-Cell Analysis of Bone-Marrow-Disseminated Tumour Cells.

So K, Su Z, Cheung J, Choi S Diagnostics (Basel). 2024; 14(19).

PMID: 39410576 PMC: 11475990. DOI: 10.3390/diagnostics14192172.


Development and validation of a multi-marker liquid bead array assay for the simultaneous detection of and hotspot mutations in single circulating tumor cells (CTCs).

Stergiopoulou D, Georgoulias V, Markou A, Lianidou E Heliyon. 2024; 10(19):e37873.

PMID: 39386783 PMC: 11462463. DOI: 10.1016/j.heliyon.2024.e37873.


Advances in the role of circulating tumor cell heterogeneity in metastatic small cell lung cancer.

Wang Q, Tan L Cancer Innov. 2024; 3(2):e98.

PMID: 38946931 PMC: 11212323. DOI: 10.1002/cai2.98.


A Capillary-Force-Driven, Single-Cell Transfer Method for Studying Rare Cells.

Amontree J, Chen K, Varillas J, Fan Z Bioengineering (Basel). 2024; 11(6).

PMID: 38927778 PMC: 11200440. DOI: 10.3390/bioengineering11060542.


The Evolution of Affordable Technologies in Liquid Biopsy Diagnostics: The Key to Clinical Implementation.

Alexandrou G, Mantikas K, Allsopp R, Yapeter C, Jahin M, Melnick T Cancers (Basel). 2023; 15(22).

PMID: 38001698 PMC: 10670715. DOI: 10.3390/cancers15225434.


References
1.
Tortola S, Steinert R, Hantschick M, Peinado M, Gastinger I, Stosiek P . Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer. J Clin Oncol. 2001; 19(11):2837-43. DOI: 10.1200/JCO.2001.19.11.2837. View

2.
Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T . Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest. 2010; 120(8):2858-66. PMC: 2912177. DOI: 10.1172/JCI37539. View

3.
Lohr J, Adalsteinsson V, Cibulskis K, Choudhury A, Rosenberg M, Cruz-Gordillo P . Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014; 32(5):479-84. PMC: 4034575. DOI: 10.1038/nbt.2892. View

4.
Magbanua M, Sosa E, Roy R, Eisenbud L, Scott J, Olshen A . Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res. 2012; 73(1):30-40. PMC: 4085329. DOI: 10.1158/0008-5472.CAN-11-3017. View

5.
Pantel K, Alix-Panabieres C . Real-time liquid biopsy in cancer patients: fact or fiction?. Cancer Res. 2013; 73(21):6384-8. DOI: 10.1158/0008-5472.CAN-13-2030. View